News

The GLISTEN clinical trial found that patients with PBC who take linerixibat experience less itching and fewer sleep disturbances.

A genetic variant near the ETS1 gene called rs10893900 increases risk for primary biliary cholangitis (PBC).

People with PBC who stay on treatment long enough to reach normal ALP levels face fewer liver complications and better long-term outcomes.

Rates of PBC recurrence after a liver transplant differed from country to country, suggesting that local factors play a role.

Nearly half of people with PBC are not being monitored as closely as guidelines recommend while taking ursodeoxycholic acid.

The Nakanuma system revealed advanced liver damage in people with PBC who didn’t respond to UDCA, which was missed by traditional systems.

Researchers found strong genetic connections between primary biliary cholangitis and muscle loss, with liver inflammation a possible driver.

Fatigue affects about two-thirds of people with PBC and can seriously impact quality of life, according to a recent review.

Studies continue to show that pruritus in PBC is undertreated, with only an estimated one-fifth of all patients receiving treatment.

The study will use a digital health tool to better record patterns of scratching and sleep during the night in patients with PBC.